Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Live Discussions
Live Discussions

Updated 20 December 2004

Role and Control of Metal-Mediated Fibril Toxicity


David Allsop

Ashley Bush

David Allsop and Ashley Bush led this live discussion on 20 December 2004. Readers are invited to submit additional comments by using our Comments form at the bottom of the page.

View Transcript of Live Discussion — Posted 22 August 2006


Background Text

We thank Bentham Science Publishers, Ltd. for providing the full text of reviews from David Allsop's (Tabner et al., 2003) and Ashley Bush's labs (Curtain et al., 2003) that serve as background for this live discussion, which is part of an ongoing series spurred by the recent special issue of Current Medicinal Chemistry-Immunology, Endocrine & Metabolic Agents on misfolded protein in disease.

See Allsop Full Text (.pdf)
See Bush Full Text (.pdf)

Introduction

Evidence for the role of metals in the toxicity of fibrillogenic proteins has grown dramatically over the last decade or so. While dietary aluminum was once touted as a potential risk factor for Alzheimer disease (a theory that still has support, see our hypothesis pages for a new twist to the aluminum debate), there is now much better evidence linking endogenous copper, iron, and zinc with the biochemistry and toxicity of amyloid-β (Aβ) and other fibrillogenic peptides, including α-synuclein. Work from Ashley Bush's lab at Massachusetts General Hospital has shown that Aβ1-42 binds Cu(II) with extremely high affinity (attomolar dissociation constant), and that completely removing the metal from solution prevents aggregation of Aβ (see Atwood et al., 2000). Similarly, Dave Schubert at the Salk Institute, together with Mordechai Chevion at the Hebrew University, has shown that iron is required for the toxicity of Aβ (Schubert and Chevion, 1995). Zinc has also been shown to precipitate aggregation of Aβ (see Bush et al., 1994). Such observations are not limited to in vitro experiments. Larry Sparks at the Sun Health Research Institute recently reported that minute amounts of copper in the drinking water can induce aggregation of Aβ in rabbit brain (see Sparks et al., 2003 and ARF related news story), while the absence of synaptic zinc in mice expressing human AβPP carrying the Swedish mutations has been correlated with reduced plaque load (see Lee et al., 2002 and ARF related news story).

How do transition metals affect Aβ biochemistry and toxicity? Do they simply provide some additional glue to keep Aβ fibrils together, or do they have a more sinister role? What about redox chemistry? Though zinc has little or no redox activity, both ferric [Fe(II)] and cupric ions [Cu(I)] can take part in the Fenton reaction, the reduction of hydrogen peroxide to hydroxyl ion and hydroxyl radical. The latter is extremely reactive and can oxidize macromolecules at rates that are comparable to diffusion speeds. In other words, hydroxyl radicals are formed and wreak havoc in an instant. Could fibrils somehow catalyze the Fenton reaction?

At Bush's lab, Xudong Huang used a chemical assay to reveal that Aβ, in the presence of Fe(III), produces hydrogen peroxide (see Huang et al., 1999), one of the Fenton ingredients. This was confirmed in David Allsop's lab by use of electron spin resonance spectroscopy (see Turnbull et al., 2001). In these experiments, Allsop's group was able to demonstrate that toxicity and production of hydrogen peroxide go hand in hand. Aβ1-42 and Aβ25-35, for example, are neurotoxic and peroxide generators, whereas AA1-15 (a fragment of the Amyloid A protein) is neither even though it aggregates. Allsop’s group has also found that α-synuclein and certain toxic forms of the prion protein also generate peroxide (see Turnbull et al. 2003 and Turnbull et al. 2003 ), suggesting that there may be a toxic mechanism common to all these fibrillogenic proteins. Cu(II) can also contribute to production of hydrogen peroxide by Aβ, but because zinc does not, it has been suggested that formation of Aβ-Zn aggregates may offer some rudimentary protection against the Aβ toxicity (see Lovell et al., 1998). All told, the evidence points to iron- or copper-mediated production of hydrogen peroxide by Aβ, followed perhaps by Fenton chemistry to produce hydroxyl radicals.

These findings are also suggestive of a therapeutic intervention-metal chelation. Bush has pioneered the use of clioquinol, which was originally developed as an antibiotic, but which also acts as a metal chelator. It is much superior to common chelators such as EDTA (ethylenediamine tetraacetic acid) because it is small and hydrophobic, and readily crosses the blood-brain barrier. In fact, recent work from Bush's lab has shown that clioquinol can substantially reduce the plaque load in APP2576 transgenic mice (Cherny et al., 2001; see also ARF related news story). It has also been shown to protect mice in an experimental model of Parkinson disease (see Kaur et al., 2003 and ARF related news story). The drug is currently in clinical trials (see our clinical trial data page).

In this live discussion, we will debate the current theories and developments pertaining to metal-related biochemistry and neurodegenerative disease, including, but not limited to:

  • Exactly what forms of aggregates produce ROS?
  • Is aggregation-mediated ROS production widespread, or limited to just a few proteins, such as Aβ, α-synuclein, and prions?
  • How can the impact of redox and non-redox metals on sporadic neurodegenerative diseases be quantitated?
  • Why are only certain neurons affected?
  • Production of hydrogen peroxide by Aβ, and Aβ toxicity—coincidence, or cause and effect?
  • Why is clioquinol, a relatively weak chelator, so effective in animal models? Is it due to a specific interaction with Aβ, and if so, can this information be used to develop more potent compounds?

We thank David Allsop and Ashley Bush for jointly leading this discussion, and we encourage you to read their recent reviews (see Background text above).—Tom Fagan.



  Submit a Comment on this Live Discussion
Cast your vote and/or make a comment on this live discussion. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 


Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Live Discussion FAQs

Webinar: A Webinar is a seminar conducted remotely over the Web. Attendees view the slides through their Web browser and hear the presentations over their own telephones.

Registration: All participants are to register by clicking on the "Register for the Webinar" link.

Access: After you register, you will receive an e-mail with a link to the Webinar and a phone number.

View Webinar Instructions

Early Detection Survey Results
The Alzheimer Disease Early Detection Surveys were designed to gauge perceptions and knowledge of early detection of Alzheimer disease as a follow-up to our Early Detection Webinar. The surveys were developed in collaboration with the Geoffrey Beene Foundation.
View Researcher Survey Results [.pdf].
View Public Survey Results [.pdf].
AlzPossible Initiative
The AlzPossible Initiative is an innovative "center without walls" that enables skilled individuals to share their knowledge about best practices in Alzheimer caregiving through this open forum.
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad